查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1793682

全球甲溝炎治療市場

Paronychia Treatment
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 371 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計2030年全球甲溝炎治療市場規模將達7.018億美元

全球甲溝炎治療市場規模預計在2024年為5.18億美元，預計在分析期內（2024-2030年）將以5.2%的複合年成長率成長，到2030年將達到7.018億美元。急性子宮內膜異位症是本報告分析的細分市場之一，預計其複合年成長率為4.3%，到分析期結束時將達到4.619億美元。慢性甲溝炎細分市場在分析期間的複合年成長率預計為7.0%。

美國市場規模估計為 1.411 億美元，中國市場預計複合年成長率為 8.1%

美國甲溝炎治療市場規模預計2024年達到1.411億美元。預計到2030年，作為世界第二大經濟體的中國市場規模將達到1.387億美元，在2024-2030年的分析期內，複合年成長率為8.1%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為2.6%和5.1%。在歐洲，預計德國市場的複合年成長率為3.3%。

全球甲溝炎治療市場－主要趨勢與促進因素摘要

人們越來越關注有效的甲溝炎治療策略是什麼？

甲溝炎是一種影響手指甲和腳趾甲周圍皮膚的發炎性疾病，由於其急性和慢性發病率高，已引起越來越多的臨床關注。甲溝炎通常由輕微創傷或長期暴露於潮濕環境中的細菌、真菌或混合感染引起，可導致嚴重不適、功能受限，有時甚至形成膿腫。糖尿病、免疫抑製或職業性刺激物暴露患者的發病率不斷上升，這促使人們對準確診斷和及時治療的需求日益增加。

治療方法因類型和嚴重程度而異。急性病例通常以局部或口服抗生素治療，並根據需要進行引流；慢性病例通常採用抗真菌治療和行為矯正，以盡量減少接觸刺激物。針對性治療、更快速的症狀緩解和預防復發的需求，促使人們採用門診聯合治療、抗菌方案和微創手術。

治療方案如何演變以應對急性疾病和慢性疾病？

對於急性細菌性甲溝炎，通常使用頭孢氨芐、克林黴素和阿莫西林-克拉維酸鉀等口服抗生素，尤其是在有蜂窩組織炎的情況下。如果膿液儲存，則在無菌條件下切開患處並引流。對於局部、輕度病例，也可使用具有抗發炎特性的外用抗生素。

慢性甲溝炎的治療已轉向抗真菌藥物（尤其是Azole或Terbinafine）合併皮質類固醇的抗發炎治療。醫生會開立隔離霜和潤膚劑來恢復皮膚完整性，並保護其免受水分和刺激物的進一步侵害。復發性或療效較差的病例需要手術治療，例如副甲狀腺切除術或部分甲剝離術。治療方法越來越個人化，取決於微生物培養結果、合併症以及病人對預防保健的依從性。

甲溝炎治療的需求將會在哪裡成長，哪些患者族群將受到最大影響？

基層醫療和皮膚科診所的需求都在成長，尤其是在都市區和職業健康領域。醫護人員、食品處理人員、游泳者以及洗手習慣不良的人屬於高危險群。患有異位性皮膚炎、糖尿病和接受免疫抑制治療的患者更容易患上慢性皮膚炎。有咬指甲和吸吮拇指習慣的兒科患者數量也在增加。

在亞太和拉丁美洲等新興市場，由於人們意識的提高和皮膚病護理可近性的提高，診斷和治療的數量正在增加。在已開發地區，人口老化和糖尿病盛行率的上升也促進了臨床需求的穩定。藥房和遠端醫療平台在提供治療可及性方面也發揮著越來越重要的作用，尤其是對於透過局部用藥和衛生教育進行治療的輕度和復發性病例。

甲溝炎治療市場的成長受到多種因素的推動。

甲溝炎治療感染疾病的成長受到許多因素的推動，例如細菌性和真菌性甲癬盛行率的上升、職業和生活方式相關風​​險因素的增加，以及人們對皮膚健康的認知不斷提高。糖尿病患者人數的增加、皮膚敏感的老年人以及免疫力缺乏的患者群體不斷壯大，需要進行急性和長期治療。

局部治療、抗生素-抗真菌聯合製劑以及微創引流技術的進步改善了臨床療效，並降低了復發率。基層醫療轉向早期診斷和自我護理，以及遠端醫療諮詢的增多，正在推動治療的發展。抗真菌藥物供應的增加、新興經濟體皮膚科服務可及性的提高以及手部和指甲衛生教育的普及，也支持了市場的持續擴張。

部分

類型（急性指甲、慢性指甲）、藥物類型（莫匹羅星軟膏、夫西地酸軟膏、慶大霉素軟膏、雙氯西林）、最終用戶（醫院/診所、皮膚病中心）

受訪公司範例

  • AbbVie Inc.
  • Allergen Plc（Allergan）
  • Bayer AG
  • BioNTech SE
  • ConvaTec Group Plc
  • Eli Lilly and Company
  • Fougera Pharmaceuticals Inc.
  • Galderma SA
  • Glenmark Generics Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Jonakayem Pharma Formulation Pvt. Ltd.
  • Merck & Co., Inc.
  • Mundipharma（with Moberg Pharma alliance）
  • NovaBay Pharmaceuticals, Inc.
  • Novartis AG
  • Perrigo New York, Inc.
  • Pfizer Inc.
  • Sandoz International GmbH
  • Taro Pharmaceutical Industries Ltd.

人工智慧整合

我們正在利用有效的專家內容和人工智慧工具來改變市場和競爭情報。

Global Industry Analysts 沒有遵循典型的 LLM 或特定於行業的 SLM查詢，而是建立了一個從世界各地的專家收集的內容庫，其中包括影片錄像、BLOG、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地和進出口（成品和原始設備製造商）情況預測其競爭地位的變化。這種複雜而多面的市場動態預計將以多種方式影響競爭對手，包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 比賽

簡介目錄
Product Code: MCP37660

Global Paronychia Treatment Market to Reach US$701.8 Million by 2030

The global market for Paronychia Treatment estimated at US$518.0 Million in the year 2024, is expected to reach US$701.8 Million by 2030, growing at a CAGR of 5.2% over the analysis period 2024-2030. Acute Paronychia, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$461.9 Million by the end of the analysis period. Growth in the Chronic Paronychia segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$141.1 Million While China is Forecast to Grow at 8.1% CAGR

The Paronychia Treatment market in the U.S. is estimated at US$141.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$138.7 Million by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.6% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Paronychia Treatment Market - Key Trends & Drivers Summarized

What Is Prompting Greater Focus on Effective Paronychia Management Strategies?

Paronychia, an inflammatory condition affecting the skin around the fingernails or toenails, is receiving increasing clinical attention due to its high prevalence across both acute and chronic forms. Commonly caused by bacterial, fungal, or mixed infections following minor trauma or prolonged moisture exposure, paronychia can lead to significant discomfort, functional limitation, and in some cases, abscess formation. The growing incidence among individuals with diabetes, immunosuppression, or occupational exposure to irritants is intensifying demand for accurate diagnosis and timely treatment.

Treatment approaches differ based on the type and severity. Acute cases are often treated with topical or oral antibiotics and drainage when necessary, while chronic paronychia typically involves antifungal therapies and behavioral modifications to minimize exposure to irritants. The need for targeted therapy, faster symptom relief, and recurrence prevention is supporting adoption of combination therapies, antiseptic regimens, and minimally invasive procedures in outpatient settings.

How Are Therapeutic Options Evolving to Address Both Acute and Chronic Forms?

For acute bacterial paronychia, oral antibiotics such as cephalexin, clindamycin, or amoxicillin-clavulanate are commonly used, especially when cellulitis is present. In cases where pus accumulation occurs, incision and drainage are performed under sterile conditions. Topical antibiotic formulations with anti-inflammatory properties are also used for localized, mild presentations.

Chronic paronychia management has shifted toward antifungal treatments, particularly topical azoles or terbinafine, combined with corticosteroids to reduce inflammation. Barrier creams and emollients are prescribed to restore skin integrity and protect against recurrent exposure to moisture and irritants. In recurrent or unresponsive cases, surgical interventions like eponychial marsupialization or partial nail avulsion may be required. Treatment regimens are increasingly personalized based on microbiological cultures, comorbid conditions, and patient adherence to preventive care.

Where Is Demand for Paronychia Treatment Growing and Which Patient Segments Are Most Affected?

Demand is growing in both primary care and dermatology clinics, particularly in urban and occupational health settings. Healthcare workers, food handlers, swimmers, and individuals with repeated hand-washing routines are at higher risk. Chronic cases are more common in those with atopic dermatitis, diabetes, or individuals on immunosuppressive therapy. Pediatric cases are also rising due to nail-biting and finger-sucking habits.

Emerging markets in Asia-Pacific and Latin America are seeing increased diagnosis and treatment as awareness improves and access to dermatological care expands. In developed regions, the aging population and higher rates of diabetes contribute to steady clinical demand. Pharmacies and telemedicine platforms are also playing a growing role in treatment access, especially for mild or recurrent cases managed with topical agents and hygiene education.

Growth in the Paronychia Treatment market is driven by several factors…

Growth in the paronychia treatment market is driven by factors such as rising prevalence of bacterial and fungal nail infections, increased exposure to occupational and lifestyle-related risk factors, and expanding awareness of dermatological health. The growing diabetic population, aging individuals with fragile skin, and immunocompromised patients contribute to a sustained patient base requiring both acute and long-term management.

Advancements in topical therapies, antibiotic-antifungal combination products, and minimally invasive drainage techniques are improving clinical outcomes and reducing recurrence. The shift toward early diagnosis and self-care in primary care settings, along with rising telehealth consultations, is increasing treatment initiation. Improved availability of antifungal agents, growing access to dermatological services in emerging economies, and wider education on hand and nail hygiene are also supporting consistent market expansion.

SCOPE OF STUDY:

The report analyzes the Paronychia Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Acute Paronychia, Chronic Paronychia); Drug Type (Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment, Dicloxacillin); End-Use (Hospitals & Clinics End-Use, Dermatology Centers End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • AbbVie Inc.
  • Allergen Plc (Allergan)
  • Bayer AG
  • BioNTech SE
  • ConvaTec Group Plc
  • Eli Lilly and Company
  • Fougera Pharmaceuticals Inc.
  • Galderma S.A.
  • Glenmark Generics Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Jonakayem Pharma Formulation Pvt. Ltd.
  • Merck & Co., Inc.
  • Mundipharma (with Moberg Pharma alliance)
  • NovaBay Pharmaceuticals, Inc.
  • Novartis AG
  • Perrigo New York, Inc.
  • Pfizer Inc.
  • Sandoz International GmbH
  • Taro Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Paronychia Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Nail Infections and Skin Disorders Spurs Demand for Effective Paronychia Treatment Options
    • Increasing Awareness of Hand and Foot Hygiene Strengthens Market for Topical and Oral Antimicrobial Therapies
    • Growing Prevalence of Chronic Conditions Such as Diabetes Throws the Spotlight on Recurrent and Complicated Paronychia Cases
    • Expansion of Dermatology Clinics and Telehealth Services Improves Access to Early Diagnosis and Prescription Treatments
    • Advancements in Antifungal and Antibacterial Drug Formulations Enhance Efficacy in Treating Both Acute and Chronic Cases
    • Rising Demand for Combination Therapies Supports the Use of Dual-Action Antibiotic and Antifungal Medications
    • Growth in At-Home Treatment Products and Over-the-Counter Creams Fuels Self-Management Among Consumers
    • Increasing Focus on Cosmetic Nail Health and Grooming Drives Demand for Preventive Treatment and Care Products
    • Surgical and Drainage Procedures for Abscess Management Expand Market for Post-Procedure Wound Care Solutions
    • Product Innovation in Moisturizing and Healing Ointments Enhances User Compliance and Recovery Outcomes
    • Rising Incidence of Occupational Nail Injuries Among Healthcare, Salon, and Construction Workers Drives Targeted Treatments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Paronychia Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Paronychia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Paronychia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Paronychia Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Acute Paronychia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Acute Paronychia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Acute Paronychia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chronic Paronychia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chronic Paronychia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Chronic Paronychia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Mupirocin Ointment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Mupirocin Ointment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Mupirocin Ointment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Fusidic Acid Ointment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Fusidic Acid Ointment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Fusidic Acid Ointment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Gentamicin Ointment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Gentamicin Ointment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Gentamicin Ointment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Dicloxacillin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Dicloxacillin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Dicloxacillin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Dermatology Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Dermatology Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Dermatology Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: China 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: China 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: China 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Paronychia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Paronychia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Paronychia Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 77: France Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: France 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: France 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: France 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Germany 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Italy 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: UK 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Spain 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Spain 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Russia 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Russia 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Paronychia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Paronychia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 16-Year Perspective for Paronychia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Australia 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Australia 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • INDIA
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 161: India Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: India 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: India 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: India 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: South Korea 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: South Korea 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Paronychia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Paronychia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Latin America 16-Year Perspective for Paronychia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Latin America 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Argentina 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Argentina 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Brazil 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Brazil 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 220: Mexico 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 223: Mexico 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Paronychia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Paronychia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 238: Middle East 16-Year Perspective for Paronychia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 241: Middle East 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 250: Iran 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 253: Iran 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 259: Israel 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 262: Israel 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 277: UAE 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 280: UAE 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030
  • AFRICA
    • Paronychia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Paronychia Treatment by Type - Acute Paronychia and Chronic Paronychia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 295: Africa 16-Year Perspective for Paronychia Treatment by Type - Percentage Breakdown of Value Sales for Acute Paronychia and Chronic Paronychia for the Years 2014, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Paronychia Treatment by Drug Type - Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 298: Africa 16-Year Perspective for Paronychia Treatment by Drug Type - Percentage Breakdown of Value Sales for Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment and Dicloxacillin for the Years 2014, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Paronychia Treatment by End-Use - Hospitals & Clinics End-Use and Dermatology Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Paronychia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use and Dermatology Centers End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION